Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in CLL and MCL undergoing alloSCT
NCT04716075Phase 2Completed
- Sponsor
- Polish Lymphoma Research Group
- Start
- Aug 2019
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), sponsored by Polish Lymphoma Research Group. Started Aug 2019; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04716075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716075.